Sam Colleen, Massaro Joseph M, D'Agostino Ralph B, Levy Daniel, Lambert Jarvis W, Wolf Philip A, Benjamin Emelia J
National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA.
Am J Cardiol. 2004 Oct 1;94(7):947-51. doi: 10.1016/j.amjcard.2004.06.038.
The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF. Anticoagulant use increased significantly in the 393 men and women (mean ages 72.5 and 79.0 years, respectively) who developed AF over the observation period: aspirin use increased from 14% to 39% in men and from 19% to 33% in women, and warfarin use increased from 10% to 39% in men and from 17% to 38% in women. There were no significant gender differences in anticoagulant use (p = 0.61), but participants using warfarin were younger. A total of 65 participants (17%) had major bleeding complications <or=5 years after initial AF. Age was not a significant predictor of bleeding.
对弗雷明汉心脏研究中1980年至1994年期间患有心房颤动（AF）的参与者记录进行回顾性审查，以确定心房颤动患者使用华法林和阿司匹林的情况。在观察期内发生心房颤动的393名男性和女性（平均年龄分别为72.5岁和79.0岁）中，抗凝剂的使用显著增加：男性阿司匹林使用率从14%增至39%，女性从19%增至33%；男性华法林使用率从10%增至39%，女性从17%增至38%。抗凝剂使用方面无显著性别差异（p = 0.61），但使用华法林的参与者年龄更小。共有65名参与者（17%）在首次发生心房颤动后≤5年出现严重出血并发症。年龄并非出血的显著预测因素。
